KAZN As a Diagnostic Marker in Ovarian Cancer: a Comprehensive Analysis Based on Microarray, MRNA-sequencing, and Methylation Data

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Jun 16

PMID 35710397

Authors

Songling Zhu

Hongxia Bao

Meng-Chun Zhang

Huidi Liu

Yao Wang

Caiji Lin

Xingjuan Zhao

Shu-Lin Liu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer (OC) is among the deadliest malignancies in women and the lack of appropriate markers for early diagnosis leads to poor prognosis in most cases. Previous studies have shown that KAZN is involved in multiple biological processes during development, such as cell proliferation, differentiation, and apoptosis, so defects or aberrant expression of KAZN might cause queer cell behaviors such as malignancy. Here we evaluated the KAZN expression and methylation levels for possible use as an early diagnosis marker for OC.

Methods: We used data from Gene Expression Omnibus (GEO) microarrays, The Cancer Genome Atlas (TCGA), and Clinical Proteomic Tumor Analysis Consortium (CPTAC) to investigate the correlations between KAZN expression and clinical characteristics of OC by comparing methylation levels of normal and OC samples. The relationships among differentially methylated sites in the KAZN gene, corresponding KAZN mRNA expression levels and prognosis were analyzed.

Results: KAZN was up-regulated in ovarian epithelial tumors and the expression of KAZN was correlated with the patients' survival time. KAZN CpG site cg17657618 was positively correlated with the expression of mRNA and the methylation levels were significantly differential between the group of stage "I and II" and the group of stage "III and IV". This study also presents a new method to classify tumor and normal tissue in OC using DNA methylation pattern in the KAZN gene body region.

Conclusions: KAZN was involved in ovarian cancer pathogenesis. Our results demonstrate a new direction for ovarian cancer research and provide a potential diagnostic biomarker as well as a novel therapeutic target for clinical application.

Citing Articles

Exploring the Potential Driver Gene Mutations That Promote Renal Cancer Cell Metastasis and Implantation Based on Circulating Tumor Cells Culture.

Hong B, Zhang X, Du X, Yang D, Hu Z, Zhang X Diagnostics (Basel). 2023; 13(11).

PMID: 37296706 PMC: 10252915. DOI: 10.3390/diagnostics13111855.

GRB10 is a novel factor associated with gastric cancer proliferation and prognosis.

Ren L, Wang Z, Sen R, Dai Z, Liao X, Shen L Aging (Albany NY). 2023; 15(9):3394-3409.

PMID: 37179120 PMC: 10449302. DOI: 10.18632/aging.204603.

References

Li Q, Jin G, Wang J, Li H, Liu H, Chang X . Live attenuated Salmonella displaying HIV-1 10E8 epitope on fimbriae: systemic and mucosal immune responses in BALB/c mice by mucosal administration. Sci Rep. 2016; 6:29556. PMC: 4944174. DOI: 10.1038/srep29556. View

Hou Y, Wang Y, Xu S, Qi G, Wu X . Bioinformatics identification of microRNAs involved in polycystic ovary syndrome based on microarray data. Mol Med Rep. 2019; 20(1):281-291. PMC: 6579986. DOI: 10.3892/mmr.2019.10253. View

Mase S, Shinjo K, Totani H, Katsushima K, Arakawa A, Takahashi S . ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer. Cancer Sci. 2019; 110(3):1105-1116. PMC: 6398878. DOI: 10.1111/cas.13936. View

Ma S, Wei P, Qu F . KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 2019; 23(11):4629-4641. DOI: 10.26355/eurrev_201906_18041. View

Gao Y, Zhou X, Zhang W . An Ensemble Strategy to Predict Prognosis in Ovarian Cancer Based on Gene Modules. Front Genet. 2019; 10:366. PMC: 6491874. DOI: 10.3389/fgene.2019.00366. View

Harrington B, Annunziata C . NF-κB Signaling in Ovarian Cancer. Cancers (Basel). 2019; 11(8). PMC: 6721592. DOI: 10.3390/cancers11081182. View

Zhao J, Huang J, Geng X, Chu W, Li S, Chen Z . Polycystic Ovary Syndrome: Novel and Hub lncRNAs in the Insulin Resistance-Associated lncRNA-mRNA Network. Front Genet. 2019; 10:772. PMC: 6715451. DOI: 10.3389/fgene.2019.00772. View

Mu X, Liu B, Hui E, Huang W, Yao L, Duo L . A rapid loop-mediated isothermal amplification (LAMP) method for detection of the macrolide-streptogramin type B resistance gene msrA in Staphylococcus aureus. J Glob Antimicrob Resist. 2016; 7:53-58. DOI: 10.1016/j.jgar.2016.07.006. View

Li N, Zhan X . Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics. EPMA J. 2019; 10(2):153-172. PMC: 6562010. DOI: 10.1007/s13167-019-00170-5. View

10.

Wang X, Han L, Zhou L, Wang L, Zhang L . Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network. Oncol Rep. 2018; 40(5):2659-2673. PMC: 6151886. DOI: 10.3892/or.2018.6707. View

11.

Tian X, Guan W, Zhang L, Sun W, Zhou D, Lin Q . Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer. J Exp Clin Cancer Res. 2018; 37(1):103. PMC: 5948853. DOI: 10.1186/s13046-018-0773-8. View

12.

Wang L, Ni S, Du Z, Li X . A six-CpG-based methylation markers for the diagnosis of ovarian cancer in blood. J Cell Biochem. 2019; 121(2):1409-1419. DOI: 10.1002/jcb.29376. View

13.

Wang Q, Lu Z, Ma J, Zhang Q, Wang N, Qian L . Six-mRNA risk score system and nomogram constructed for patients with ovarian cancer. Oncol Lett. 2019; 18(2):1235-1245. PMC: 6607424. DOI: 10.3892/ol.2019.10404. View

14.

Zheng J, Zhou Y, Li X, Hu J . MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression. Eur Rev Med Pharmacol Sci. 2019; 23(16):6839-6848. DOI: 10.26355/eurrev_201908_18723. View

15.

Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q . Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019; 7(1):156. PMC: 6587259. DOI: 10.1186/s40425-019-0629-6. View

16.

Luo M, Zhou L, Zhan S, Cheng L, Li R, Wang H . ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway. Biochem Biophys Res Commun. 2019; 513(2):528-533. DOI: 10.1016/j.bbrc.2019.04.016. View

17.

Chen Y, Bi F, An Y, Yang Q . Identification of pathological grade and prognosis-associated lncRNA for ovarian cancer. J Cell Biochem. 2019; 120(9):14444-14454. DOI: 10.1002/jcb.28704. View

18.

Mohamed N, Hay T, Reed K, Smalley M, Clarke A . APC2 is critical for ovarian WNT signalling control, fertility and tumour suppression. BMC Cancer. 2019; 19(1):677. PMC: 6617595. DOI: 10.1186/s12885-019-5867-y. View

19.

Goicoechea S, Zinn A, Awadia S, Snyder K, Garcia-Mata R . A RhoG-mediated signaling pathway that modulates invadopodia dynamics in breast cancer cells. J Cell Sci. 2017; 130(6):1064-1077. PMC: 5358339. DOI: 10.1242/jcs.195552. View

20.

Zhou Y, Zhu S, Yang D, Zhao D, Li J, Liu S . Characterization of Klebsiella sp. strain S1: a bacterial producer of secoisolariciresinol through biotransformation. Can J Microbiol. 2016; 63(1):1-10. DOI: 10.1139/cjm-2016-0266. View